Circadian Therapeutics and Arquimea Collaboration

Jul 22, 2021

Circadian Therapeutics and ARQUIMEA sign a collaboration agreement for the development of casein kinase 1 inhibitors for the treatment of diseases affecting the nervous system

  • Co-development of molecules as an innovative treatment for nervous system diseases such as ALS, Parkinson’s or Alzheimer’s disease.
  • Lead molecule, AP-2, is able to cross the blood-brain barrier and act directly on the brain with an innovative mechanism of action.
  • The agreement will increase the chances of success, making more efficient progress in the treatment of several neurodegenerative diseases for which there is still no cure.

Therapeutics that treat the causes, not just the symptoms

Contact

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

contact@circadiantherapeutics.com

+44 (0) 1865 546581

Registered Office

Oxford Centre for Innovation
New Road
Oxford
OX1 1BY

Registered No 10283353.

PRIVACY POLICY

© Circadian Therapeutics 2018.
All rights reserved.

Website Design by Brand Cooke

Accessibility